AD/PD 2023 and Biomarkers View overview page

Random forests in large-scale omics studies

Detecting retinal Aβ: a promising path for non-invasive Alzheimer’s disease diagnosis

Prospects for Alzheimer’s disease monitoring and treatment in 2023

Streamlining dementia diagnosis with digital biomarkers

Trends in the use of surrogate biomarkers during clinical trials

Digital markers detect changes in neurocognitive performance in those with vs without hearing loss

Research needs: determining reliability and robustness of plasma markers in Alzheimer’s disease

Blood biomarkers for the differential diagnosis of Alzheimer’s disease in clinical practice

Decreased kidney function associated with increased plasma p-tau levels

Validating blood-based biomarker assays for use in Alzheimer’s disease clinical care

Relationship between amyloid and tau modulated by astrocyte reactivity

Sex and gender biases in AI

Comparing the performance of blood-based amyloid and tau assays

BBB disruption impacts amyloid biomarker performance

Correlation between synaptic biomarkers and known CSF biomarkers in Alzheimer’s disease

Alzheimer’s disease subtypes identified based on blood proteomics